Indian IT and pharma stocks are not benefiting from a weaker rupee as expected. Tariff concerns are overshadowing currency gains. Investors are waiting for clarity on trade deals. Foreign investors have also been selling these stocks. Valuations remain a concern for pharma companies. Demand for IT services shows signs of improvement. Stock selection will be crucial for investors.
FIIs sold about Rs 11,000 crore worth Indian stocks in 2 days of US-Iran war
Foreign investors sold nearly Rs 11,000 crore in two March sessions amid escalating West Asia tensions, surging crude prices and currency volatility. DIIs offered support,